Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2026)

Monopar Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $4.1 million in Q3 2025.

• Quarterly Operating Expenses rose 159.89% year-over-year to $4.1 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $10.5 million (up 59.7% YoY) and the FY2024 annual result came in at $4.6 million, changed N/A from the prior year.
• Operating Expenses improved to $4.1 million in Q3 2025 per MNPR's latest filing, from $3.2 million in the prior quarter.
• Over five years, Operating Expenses peaked at $4.1 million in Q3 2025 and troughed at $1.5 million in Q4 2024.
• A 5-year average of $2.4 million and a median of $2.4 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 31.75% in 2024, then soared 159.89% in 2025.
• Over 5 years, Operating Expenses stood at $2.7 million in 2021, then grew by 8.5% to $2.9 million in 2022, then slipped by 28.98% to $2.1 million in 2023, then decreased by 26.49% to $1.5 million in 2024, then jumped by 169.52% to $4.1 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $4.1 million, $3.2 million, and $3.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.